Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for …
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease …
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital …
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and …
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology …
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for …
Delta4 expands Team and tackles new indications
A Welcome to Our Newest Member Following our Financing in March 2021 and our move into new premises in July …
Office News – July ’21
We are excited to announce that Delta4 has moved into a new office in the 8th district, close to the city …
Alfred Steininger to Join Delta4 as CFO
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings …
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified …
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed …
Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in …
BIO-Europe 2020 Digital – Partnering Event
Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to …
Sachs 20th Annual Biotech In Europe Forum
The 20th Annual Biotech in Europe (BEF) Forum is recognized as the leading international Stage for those interested in investing …
World Orphan Drug Congress
With over 1,500 attendees from 50+ countries, the 2020 edition of the World Orphan Drug Congress USA was held online …
Press Release – June 2020
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its …
COVID-19 – Call to Action
The global crisis caused by the SARS-Cov2 outbreak requires rapidly applicable therapeutics. Available approved drug substances represent one of the …
Biotech Showcase 2020 @JPM San Francisco
What Is It? Biotech Showcase™ is an investor conference during JPM 2020, devoted to providing private and public biotech companies …
LSX Investival Showcase London
Returning for its fourth year, LSX’s Investival Showcase continues and expands upon its exclusive partnership with global investment bank Jefferies, …
Life-Science Investment Days, Vienna
Delta4 will be on-site at the Life-Science Investment Days on November 8th in Vienna. The Life Science Investment Days Contact us to make …
Rising Stars at BEF19
Delta4 was presenting at the Biotech in Europe Investment Forum 2019 in Basel in the “Rising Stars” session – contact …
Meet us at BEF19 in Basel
Delta4 will be presenting at the 19th Annual Biotech in Europe Forum in Basel. Contact us to make an appointment.